

A photograph of a family. A man with glasses and a beard is smiling and holding a baby. A woman is leaning in, looking at the baby. The baby is wearing a light-colored sweater. The background is blurred.

# BioGaia<sup>®</sup>

## Interim Report

January - June 2025

# Q2 2025

## SECOND QUARTER 2025

Net sales amounted to SEK 404.7 million (384.1), an increase of SEK 20.6 million, or an increase of 5% (excluding foreign exchange effects an increase of 13.2%).

Net sales in the Pediatrics segment amounted to SEK 310.1 million (304.8), an increase of 2% (excluding foreign exchange effects an increase of 9%).

Net sales in the Adult Health segment amounted to SEK 89.8 million (78.2), an increase of 15% (excluding foreign exchange effects an increase of 23%).

Operating expenses amounted to SEK 185.5 million (148.7), an increase of SEK 36.9 million (25%). Operating expenses, excluding items affecting comparability, increased by 23% to SEK 185.5 million (151.4).

Operating profit decreased by 20% to SEK 108.3 million (135.4), which corresponds to an operating margin of 27% (35%).

Adjusted operating profit decreased by 18% to SEK 108.3 million (132.6), which corresponds to an adjusted operating margin of 27% (35%).

Profit after tax amounted to SEK 87.9 million (111.0), a decrease of 21%.

Earnings per share amounted to SEK 0.87 (1.10) before and after dilution. Cash flow amounted to SEK -623.8 million (-582.2). Cash and cash equivalents amounted to SEK 622.3 million (1,007.7).

### Key events in the second quarter of 2025

On May 7 BioGaia announced that it is expanding its global footprint by establishing direct sales in the Netherlands initially through an online approach.

On May 30 BioGaia announced that the number of votes in BioGaia decreased as a result of the conversion of a total of 1,038,202 Class A shares into 1,038,202 Class B shares.

## FIRST HALF 2025

Net sales amounted to SEK 771.0 million (753.9), an increase of SEK 17.0 million, or an increase of 2% (excluding foreign exchange effects an increase of 5.0%).

Net sales in the Pediatrics segment amounted to SEK 580.0 million (597.1), a decrease of 3% (excluding foreign exchange effects a decrease of 0%).

Net sales in the Adult Health segment amounted to SEK 184.4 million (153.0), an increase of 20% (excluding foreign exchange effects an increase of 23%).

Operating expenses amounted to SEK 356.8 million (271.3), an increase of SEK 85.5 million (31%). Operating expenses, excluding items affecting comparability, increased by 33% to SEK 356.8 million (269.1).

Operating profit decreased by 26% to SEK 205.5 million (278.6), which corresponds to an operating margin of 27% (37%).


Adjusted operating profit decreased by 27% to SEK 205.5 million (280.8), which corresponds to an adjusted operating margin of 27% (37%).

Profit after tax amounted to SEK 168.1 million (232.9), a decrease of 28%.

Earnings per share amounted to SEK 1.66 (2.31) before and after dilution. Cash flow amounted to SEK -590.5 million (-541.4).

### Key events after the end of the second quarter of 2025

On July 16 BioGaia announced that it launches a subsidiary company - BioGaia New Sciences AB - dedicated to advancing microbiome research and innovation beyond its core business.



	Apr - Jun 2025	Apr - Jun 2024
Net sales, SEK thousands	404,692	384,122
Growth in net sales	5%	22%
Operating profit, SEK thousands	108,346	135,377
Operating margin	27%	35%
Profit after tax, SEK thousands	87,906	111,010
Number of shares before dilution, thousands	101,162	100,982
Number of shares after dilution, thousands	101,162	100,992
Earnings per share before dilution, SEK	0.87	1.10
Earnings per share after dilution, SEK	0.87	1.10

This information is information that BioGaia AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the CEO, at 08.00 a.m. CEST on 18 July 2025.

# Q2 2025

## BioGaia AB (publ.) Interim report 2025

The Board of Directors and the CEO of BioGaia AB hereby present the interim report for the period 1 January – 30 June 2025.

### CEO's comment

#### Continued solid growth

Strong sales momentum returned in the second quarter, supported by high demand in key markets, especially in the APAC region and North America. Sales for the quarter were up 5%, but when factoring in the strengthening SEK, sales were up 13,2% for the quarter and 5% year to date.

Particularly noteworthy in the quarter was the strong sales in the Adult Health segment that net of currency effects was up 23% and the Pediatric segment grew 9%.

Year to Date net of currency effects the Adult Health segment was up 23% and the Pediatric segment was flat.

It is noteworthy how well our increased focus on Adult Health is paying off with strong growth for our BioGaia Gastrus and BioGaia Protectis tablets. It should also be mentioned that BioGaia Prodentis and Prodentis Kids is growing rapidly.

Year to Date the Americas region continues its strong growth at 21%, with the US market continuing to lead the way. Noteworthy is strong sales in Chile and Guatemala.

Year to Date sales for the APAC region was -1% but sales for the Second Quarter was strong at 15% driven by online sales and both medical and consumer marketing activities. The Indonesian market is performing well.

EMEA sales year to date declined 13%. This is partially due the termination of our local partner agreement in France and the start-up of our direct distribution through our own subsidiary – a successful strategy we are now continuing in France.

In the Second quarter we opened the Netherlands market using a digital-first strategy, a slightly different approach from our strategy mentioned above. This allows us to test this new market potential before establishing a subsidiary. Early results have been encouraging and outperforming our initial expectations.

#### Operating profit decline reflects increased marketing investments

Year to date adjusted operating profit decreased by 27% and corresponds to an adjusted operating margin of 27%. This is a result of our current increased marketing investments and opening of new direct businesses.

#### New evidence highlights BioGaia Protectis' impact on children's gut health

New clinical evidence highlights the effectiveness of BioGaia Protectis in preventing antibiotic-associated diarrhea in children. A recently published large-scale, randomized, placebo-controlled clinical trial further strengthens the evidence for BioGaia Protectis (*L. reuteri* DSM 17938) in supporting gut health in children.

The study showed a significant reduction in antibiotic-associated diarrhea by 54% among children taking our probiotic vs placebo, particularly in younger age groups and those treated for ear infections. Results like these not only validate the efficacy of our products but also reinforce BioGaia's position as a trusted leader in pediatric probiotics.

#### Successful participation in key medical congresses

In the quarter, we participated in two important medical congresses. At the International Association for Dental, Oral, and Craniofacial Research (IADR) in Barcelona, we showcased BioGaia oral health probiotic products and hosted a symposium on the oral microbiome's role in oral health. At the European Society for Pediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) Congress in Helsinki, our symposium highlighted advances in pediatric gut health, featuring leading experts and presenting promising pre-clinical data on our next-generation probiotic strain BG-R46®.

#### Proud to be recognized by TIME for Sustainable Growth Leadership

BioGaia has been recognized by TIME Magazine and Statista as one of the World's Top 500 Companies pairing strong growth with environmental stewardship. This honor underscores our commitment to sustainable business practices, balancing robust financial performance with responsible environmental management. From innovative packaging solutions to rigorous ESG standards and transparent reporting, we continue to integrate sustainability into every aspect of our operations.

#### Executing on our strategic investments to strengthen our brand and direct sales

Passing the mid-point of 2025 we are pleased with the results of our strategic investments to strengthen the BioGaia brand and expand our direct business. This past quarter, we advanced targeted consumer marketing initiatives to boost awareness and engagement in key direct markets.

As mentioned and in line with our strategic direction, our direct business presence continues to grow with newer direct markets such as France and the Netherlands, and our established direct markets like the USA, Canada, Australia, Finland and the UK continue to show excellent sales growth. Our direct businesses now represent 36% of our sales.

I am confident that our ongoing investments in the BioGaia brand, direct markets, and R&D will unlock long-term value and strengthen our leadership in probiotics.



**Theresa Agnew**  
President and CEO, BioGaia  
18 July 2025



Teleconference: Investors, analysts, and the media are invited to take part in a teleconference on the interim report to be held today, 18 July 2025, at 09:30 a.m. CEST with CEO Theresa Agnew and CFO Alexander Kotsinas. More information about the teleconference is available here <https://financialhearings.com/event/51893>.

# Q2 2025

## Revenue

SEKm	Apr - Jun 2025	Apr - Jun 2024	Change
Pediatrics	310.1	304.8	2%
Adult Health	89.8	78.2	15%
Other	4.8	1.1	336%
<b>Total</b>	<b>404.7</b>	<b>384.1</b>	<b>5%</b>

SEKm	Apr - Jun 2025	Apr - Jun 2024	Change
EMEA	136.7	137.4	-1%
APAC	111.7	97.5	15%
Americas	156.3	149.3	5%
<b>Total</b>	<b>404.7</b>	<b>384.1</b>	<b>5%</b>

	Jan - Jun 2025	Jan - Jun 2024	Change
Pediatrics	580.0	597.1	-3%
Adult Health	184.4	153.0	20%
Other	6.6	3.8	74%
<b>Total</b>	<b>771.0</b>	<b>753.9</b>	<b>2%</b>

	Jan - Jun 2025	Jan - Jun 2024	Change
EMEA	260.3	298.9	-13%
APAC	180.8	183.3	-1%
Americas	329.8	271.8	21%
<b>Total</b>	<b>771.0</b>	<b>753.9</b>	<b>2%</b>

## SALES SECOND QUARTER

Consolidated net sales amounted to SEK 404.7 million (384.1), which is an increase of SEK 20.6 million, or an increase of 5% (excluding foreign exchange effects an increase of 13%).

Sales in EMEA amounted to SEK 136.7 million (137.4), a decrease of 1%, which was due to lower sales in the Pediatrics segment, while sales increased in the Adult Health segment. Sales decreased mainly in Turkey, France and Germany. Sales for the quarter were negatively impacted by the decision to start selling direct in France.

Sales in APAC amounted to SEK 111.7 (97.5), an increase of 15%, which was due to higher sales in the Pediatrics and the Adult Health segments. Sales increased mainly in Indonesia, Australia and South Korea.

Sales in Americas totaled SEK 156.3 million (149.3), up 5% due to increased sales in the Adult Health segment, while sales decreased in the Pediatrics segment. Sales increased mainly in USA and Guatemala.

## SALES FIRST HALF YEAR

Consolidated net sales amounted to SEK 771.0 million (753.9), which is an increase of SEK 17.0 million, or an increase of 2% (excluding foreign exchange effects an increase of 5%). Over the past 12-month period, sales increased 5%.

Sales in EMEA amounted to SEK 260.3 million (298.9), a decrease of 13%, which was due to lower sales in the Pediatrics and the Adult Health segments. Sales decreased mainly in France, Germany and Turkey. Sales were negatively impacted by the decision to start selling direct in France.

Sales in APAC amounted to SEK 180.8 (183.3), a decrease of 1%, which was due to lower sales in the Pediatrics segment, while sales increased in the Adult Health segment. Sales decreased mainly in China due to quarterly variations for individual orders.

Sales in Americas totaled SEK 329.8 million (271.8), up 21% due to increased sales in the Pediatrics and the Adult Health segments. Sales increased mainly in USA, Chile and Guatemala.

## Net sales bridge second quarter

SEKm		Change
2024	384.1	
Foreign exchange	-30.1	-7.8%
Organic growth	50.6	13.2%
<b>2025</b>	<b>404.7</b>	<b>5.4%</b>

## Net sales bridge first half year

SEKm		Change
2024	753.9	
Foreign exchange	-20.3	-2.7%
Organic growth	37.4	5.0%
<b>2025</b>	<b>771.0</b>	<b>2.3%</b>

# Q2 2025

## Pediatrics



The Pediatrics segment accounts for approximately 75% of BioGaia's total sales. BioGaia Protectis drops remain the most sold product and are sold in more than 100 countries. Other key products within the Pediatrics segment include Protectis tablets, oral rehydration solution as well as cultures to be used as ingredients in licensee products.

SEKm	Apr - Jun 2025	Apr - Jun 2024	Change	Jan - Jun 2025	Jan - Jun 2024	Change
Pediatrics	310.1	304.8	2%	580.0	597.1	-3%

### SALES SECOND QUARTER

Sales in the Pediatrics segment amounted to SEK 310.1 million (304.8), an increase of 2% (excluding foreign exchange effects an increase of 9%).

Sales of BioGaia Protectis drops decreased in Americas and EMEA, while sales increased in APAC, compared to the corresponding period last year. Sales increased mainly in USA, Guatemala and Chile.

Sales of BioGaia Protectis tablets within the Pediatrics segment increased compared to the corresponding period last year. Sales increased in APAC and EMEA, mainly in Spain and South Africa.

### SALES FIRST HALF YEAR

Sales in the Pediatrics segment amounted to SEK 580.0 million (597.7), a decrease of 3% (excluding foreign exchange effects, a change of 0%).

Sales of BioGaia Protectis drops decreased in EMEA and APAC and increased in Americas compared to the corresponding period last year. Sales increased mainly in USA, Guatemala and Chile.

Sales of BioGaia Protectis tablets within the Pediatrics segment slightly decreased compared to the corresponding period last year. Sales decreased mainly in Brazil and the Philippines despite increased sales in USA.

# Q2 2025

## Adult Health



The Adult Health segment accounts for approximately 25% of BioGaia's total sales. Sales mainly comprise BioGaia Protectis, BioGaia Gastrus, BioGaia Prodentis, BioGaia Osortis, as well as cultures as an ingredient in a licensee's dairy products and Nutraceuticals' own products.

SEKm	Apr - Jun 2025	Apr - Jun 2024	Change
Adult Health	89.8	78.2	15%

Jan - Jun 2025	Jan - Jun 2024	Change
184.4	153.0	20%

### SALES SECOND QUARTER

Sales in the Adult Health segment amounted to SEK 89.8 million (78.2), an increase of 15% (excluding foreign exchange effects, an increase of 23%).

Sales of BioGaia Protectis tablets increased compared to the corresponding period last year. Sales increased in EMEA and APAC, mainly in South Africa and Japan.

Sales of BioGaia Gastrus increased compared to the corresponding period last year, mainly in USA.

Sales of BioGaia Prodentis increased compared to the corresponding period last year. Sales increased in Americas and APAC, mainly in USA and Indonesia.

### SALES FIRST HALF YEAR

Sales in the Adult Health segment amounted to SEK 184.4 million (153.0), an increase of 20% (excluding foreign exchange effects, an increase of 23%).

Sales of BioGaia Protectis tablets increased compared to the corresponding period last year. Sales increased in APAC, mainly in Hong Kong and South Korea.

Sales of BioGaia Gastrus increased compared to the corresponding period last year. Sales increased in all regions, mainly in USA.

Sales of BioGaia Prodentis increased compared to the corresponding period last year. Sales increased in Americas, mainly in USA.

# Q2 2025

## Earnings

### SECOND QUARTER

#### Gross margin

The total gross margin amounted to 73% (74%).

The gross margin for the Pediatrics segment amounted to 74% (77%) and for the Adult Health segment to 66% (61%). The Adult Health gross margin increased compared to the same quarter last year due to a more favorable geographic sales mix effect and previous price increases.

#### Operating expenses and operating profit

Operating expenses amounted to SEK 185.5 million (148.7), an increase of SEK 36.9 million (25%) mainly due to increased selling expenses and exchange losses on receivables. Operating expenses, excluding items affecting comparability, increased by 23% to SEK 185.5 million (151.4). There were no items affecting comparability in the quarter. Items affecting comparability in the same quarter last year include the reversal of an accrual for litigation fees in connection with the termination of the distribution agreement in Italy and costs related to terminating rental premises.

Selling expenses amounted to SEK 138.4 million (110.3), an increase of 25%, mainly due to higher costs for sales and marketing activities mainly in subsidiaries.

R&D expenses amounted to SEK 30.4 million (26.8), an increase of 13%, mainly due to increased clinical study costs in the quarter.

Administrative expenses amounted to SEK 12.0 million (5.8), an increase of 108%. Administrative expenses were higher this quarter, whereas in the same quarter last year they were lower due to the reversal of an accrual for litigation fees in connection with the termination of the distribution agreement in Italy and costs related to terminating rental premises.

Other operating expenses refers to exchange losses on receivables and liabilities of an operating nature and amounted to SEK 4.8 million (5.8).

Operating profit amounted to SEK 108.3 million (135.4), a decrease of 20%. The operating margin was 27% (35%).

Adjusted operating profit amounted to SEK 108.3 million (132.6), a decrease of 18%. The adjusted operating margin was 27% (35%).

Net financial items amounted to SEK 2.1 million (7.4). Net financial items were impacted by the adjustment of the value of the earn-out in relation to Nutraceuticals in the amount of SEK -1.6 million (-1.0).

#### Profit after tax and earnings per share

Profit after tax amounted to SEK 87.9 million (111.0), a decrease of 21%. The effective tax rate was 20% (22%).

Earnings per share amounted to SEK 0.87 (1.10) before dilution and SEK 0.87 (1.10) after dilution.

### FIRST HALF YEAR

#### Gross margin

The total gross margin amounted to 73% (73%).

The gross margin for the Pediatrics segment amounted to 75% (76%) and for the Adult Health segment to 66% (59%). The Adult Health gross margin increased compared to the same quarter last year due to a more favorable geographic sales mix effect and previous price increases.

#### Operating expenses and operating profit

Operating expenses amounted to SEK 356.8 million (271.3), an increase of SEK 85.5 million (31%). Operating expenses, excluding items affecting comparability, increased by 33% to SEK 356.8 million (269.1). There were no items affecting comparability in the period. Items affecting comparability in the same period last year include the reversal of an accrual for litigation fees in connection with the termination of the distribution agreement in Italy and costs related to terminating rental premises.

Selling expenses amounted to SEK 251.5 million (206.3), an increase of 22%, due to higher costs for sales and marketing activities mainly in subsidiaries.

R&D expenses amounted to SEK 53.1 million (51.9), an increase of 2%.

Administrative expenses amounted to SEK 23.1 million (19.7), an increase of 17%. Administrative expenses were higher this year, whereas in the same quarter last year they were lower due to the reversal of an accrual for litigation fees in connection with the termination of the distribution agreement in Italy and costs related to terminating rental premises.

Other operating expenses refers to exchange losses on receivables and liabilities of an operating nature and amounted to SEK 29.2 million (-6.6).

Operating profit amounted to SEK 205.5 million (278.6), a decrease of 26%. The operating margin was 27% (37%).

Adjusted operating profit amounted to SEK 205.5 million (280.8), a decrease of 27%. The adjusted operating margin was 27% (37%). Items affecting comparability in the same period last year include the reversal of an accrual for litigation fees in connection with the termination of the distribution agreement in Italy and costs related to terminating rental premises.

Net financial items amounted to SEK 6.8 million (17.8). Net financial items were impacted by the adjustment of the value of the earn-out in relation to Nutraceuticals in the amount of SEK -3.5 (-2.2) million.

#### Profit after tax and earnings per share

Profit after tax amounted to SEK 168.1 million (232.9), a decrease of 28%. The effective tax rate was 21% (21%).

Earnings per share amounted to SEK 1.66 (2.31). There are no significant dilutive effects.

#### Parent Company

The Parent Company's net sales amounted to SEK 586.1 million (624.0) and profit before tax was SEK 175.2 million (263.5). The two clinical studies in BioGaia Pharma did not meet their primary endpoints although there were positive trends and the company is now investigating out licensing opportunities. The financial net includes a write-down of the shares in BioGaia Pharma AB amounting to 21.1 million. The financial performance of the Parent Company is in all material respects aligned with that of the Group.

# Q2 2025

## Balance sheet and cash flow

### Balance sheet 30 June 2025

Total assets amounted to SEK 1,432.5 million (2,034.0).

Goodwill from the acquisition of Nutraceutics was adjusted for currency translation. The financial liability for the additional purchase price was value adjusted. For more information, see Note 3.

Compared with the preceding year, receivables increased whereas payables and inventory decreased.

Cash and cash equivalents on 30 June 2025 amounted to SEK 622.3 million (1,224.0).

### Cash flow second quarter

Cash flow amounted to SEK -623.8 million (-582.2). Cash flow includes dividends of SEK 698.0 million (696.8).

Cash flow from operating activities amounted to SEK 77.2 million (119.1). The decrease in cash flow in operations compared with the year-earlier period was due to lower operating profit and a negative change in working capital.

Cashflow from investing activities amounted to SEK 1.2 million (2.2).

### Cash flow first half year

Cash flow amounted to SEK -590.5 million (-541.4). The cash flow includes a dividend payment of SEK 698.0 million (696.8).

Cash flow from operating activities amounted to SEK 112.9 million (171.1). The decrease in cash flow in operations compared with the year-earlier period was mainly due to a lower operating profit.

Cashflow from investing activities amounted to SEK 1.9 million (11.0).

## Other disclosures

### Employees

The number of employees in the Group on 30 June 2025 totaled 230 (220 on 30 June 2024).

The company has an incentive program for all employees based partly on the company's sales and profit and partly on individual targets. The maximum bonus is equal to 12% of annual salary. In addition to this program, BioGaia has also implemented an employee stock option program as resolved by the 2024 Annual General Meeting. 490,000 stock options were granted on the 16<sup>th</sup> of March 2025 whereof 305,000 were granted to management. IFRS 2 has been used to calculate the costs associated with the program. The costs are SEK 0.5 million in the quarter. Furthermore, the 2025 Annual General Meeting resolved on a performance share plan for employees that is currently being implemented. Further details about the programs are available on [biogaia.com](https://biogaia.com) under Annual General Meetings 2024 and 2025.

### Future outlook

BioGaia's goal is to create strong value growth and a good return for its shareholders. This will be achieved through a greater emphasis on the BioGaia brand, online sales, increased sales to both existing and new customers and a controlled cost level.

The long-term financial target is an operating margin of at least 34% with continued strong growth and increased investments in research, product development, brand building and in the sales organization. BioGaia's dividend policy is to pay a shareholder dividend equal to 50% of profit after tax in the Group excluding non-recurring items. For the coming years BioGaia intends to give extra dividends of 50% to 100% of profit after tax in the Group excluding non-recurring items, provided that the future cash flows are in line with BioGaia's projections.

In view of the company's strong portfolio consisting of an increased number of innovative products that are sold predominantly under the BioGaia brand, successful clinical trials and a strong distribution network that covers a large share of key markets for BioGaia, BioGaia's future outlook remains bright.

### Significant risks and uncertainties – Group and Parent Company

Significant risks and uncertainties are described in the administration report of the annual report for 2024 on pages 137 and 138 and in Notes 26 and 27. No significant changes in these risks and uncertainties are assessed to have taken place on 30 June 2025 except for increased geopolitical and trade uncertainties, including challenging global economic conditions, market trends and the imposition of tariffs and sanctions.

### Related party transactions

During the quarter Annwall & Rothschild Investment AB sold 3,703,340 class A shares and 500,000 class B shares, corresponding to 4.2% of the share capital and 27.9% of the voting rights in BioGaia AB. Annwall & Rothschild Investment AB is owned by Peter Rothschild and Jan Annwall. Peter Rothschild is Chairman of the Board of BioGaia AB and receives a director's fee of SEK 950,000 per year. During the quarter, Peter Rothschild received additional remuneration for significant working duties, in addition to his assignment on the Board, of SEK 35,000 in accordance with the decision of the Annual General Meeting and the Board of Directors.

# Q2 2025

## Key events in the second quarter of 2025

### Launches

Distributor	Country	Product
Pemix	Malta	BioGaia Gastrus
Abbott	Jordan	BioGaia Protectis drops
BioGaia	Sweden	BioGaia Gastrus Pure Action
Ewopharma	Poland	BioGaia Gastrus Pure Action
BG Distribution	Hungary	BioGaia Gastrus Pure Action

### BioGaia establishes direct sales in the Netherlands.

On May 7 BioGaia announced that it is expanding its global footprint by establishing direct sales in the Netherlands initially through an online approach.

### Change in number of votes in BioGaia.

On May 30 BioGaia announced that the number of votes in BioGaia decreased as a result of the conversion of a total of 1,038,202 Class A shares into 1,038,202 Class B shares.

## Key events after the end of the second quarter of 2025

### BioGaia launches BioGaia New Sciences.

On July 16 BioGaia announced that it launches a subsidiary company – BioGaia New Sciences AB – dedicated to advancing microbiome research and innovation beyond its core business.

## Accounting policies

This interim report has been prepared for the Group in accordance with IAS 34 Financial Reporting and the Swedish Annual Accounts Act, and for the Parent Company in accordance with the Swedish Annual Accounts Act. Disclosures according to IAS 34 Interim Financial Reporting are provided both in notes and elsewhere in the interim report. The consolidated financial statements have been prepared in compliance with the International Financial Reporting Standards (IFRS) issued by the International Accounting Standards Board (IASB) and interpretations from the International Financial Reporting Interpretations Committee (IFRIC) that have been approved by the European Commission for application in the EU. The accounting policies applied by the Group and the Parent Company are consistent with the accounting policies applied in preparation of the most recent annual report.

The Parent Company prepares its financial statements in accordance with RFR 2 Accounting for Legal Entities, and the Swedish Annual Accounts Act, and applies the same accounting policies and valuation methods as in the most recent annual report.

For balance sheet items, figures in parentheses refer to previous year-end figures. For income statement and cash flow items, they refer to the same period previous year.

## New accounting standards

Management's assessment is that new and amended standards and interpretations that came into force in 2025 have not had a material effect on the Group's financial statements. Management's assessment is that new and amended standards and interpretations that have not yet come into effect will not have a material effect on the Group's financial statements for the period of initial application.

# Q2 2025

## Summary of consolidated statements of comprehensive income

(Amounts in SEK 000s)	Apr - Jun 2025	Apr - Jun 2024	Jan - Jun 2025	Jan - Jun 2024	Jan - Dec 2024	Jul 2024 - Jun 2025	Jul 2023 - Jun 2024
Net sales (Note 1)	404,692	384,122	770,957	753,918	1,422,718	1,439,757	1,369,386
Cost of sales	-110,811	-100,081	-208,712	-204,048	-391,975	-396,639	-358,276
Gross profit	293,881	284,041	562,245	549,870	1,030,743	1,043,118	1,011,110
Selling expenses	-138,354	-110,276	-251,456	-206,258	-422,657	-467,855	-391,723
Administrative expenses	-11,998	-5,756	-23,086	-19,682	-41,621	-45,025	-37,790
Research and development expenses	-30,390	-26,826	-53,058	-51,940	-157,104	-158,222	-101,216
Other operating income/ expense	-4,792	-5,806	-29,161	6,570	14,010	-21,721	-1,753
Operating profit	108,346	135,377	205,483	278,560	423,371	350,294	478,628
Financial income	4,579	8,856	11,459	20,817	39,372	30,014	52,418
Financial expenses	-2,524	-1,481	-4,629	-3,026	-14,924	-16,527	-18,482
Profit before tax	110,401	142,752	212,313	296,351	447,819	363,781	512,564
Tax	-22,495	-31,742	-44,210	-63,494	-96,431	-77,147	-110,847
<b>Profit for the period</b>	<b>87,906</b>	<b>111,010</b>	<b>168,103</b>	<b>232,857</b>	<b>351,388</b>	<b>286,634</b>	<b>401,717</b>
Gains/losses arising on translation of the statements of foreign operations	-9,620	-2,581	-34,675	13,287	22,565	-25,397	-9,036
<b>Comprehensive income for the period</b>	<b>78,286</b>	<b>108,429</b>	<b>133,428</b>	<b>246,144</b>	<b>373,953</b>	<b>261,237</b>	<b>392,681</b>
<b>Profit for the period attributable to:</b>	87,906	111,010	168,103	232,857	351,388	286,634	401,717
Owners of the Parent Company	-	-	-	-	-	-	-
Non-controlling interests	-	-	-	-	-	-	-
<b>Profit for the period</b>	<b>87,906</b>	<b>111,010</b>	<b>168,103</b>	<b>232,857</b>	<b>351,388</b>	<b>286,634</b>	<b>401,717</b>
<b>Comprehensive income for the period attributable to: Owners of the Parent Company</b>	78,286	108,429	133,428	246,144	373,953	261,237	392,681
Non-controlling interests	-	-	-	-	-	-	-
<b>Comprehensive income for the period</b>	<b>78,286</b>	<b>108,429</b>	<b>133,428</b>	<b>246,144</b>	<b>373,953</b>	<b>261,237</b>	<b>392,681</b>
<b>Earnings per share</b>							
Earnings per share before dilution, (SEK)	0.87	1.10	1.66	2.31	3.48	2.83	3.98
Earnings per share after dilution, (SEK)	0.87	1.10	1.66	2.31	3.48	2.83	3.98
Number of shares (thousands)	101,162	100,982	101,162	100,982	101,162	101,162	100,982
Average number of shares before dilution, (thousands)	101,162	100,982	101,162	100,982	101,072	101,117	100,982
Average number of shares after dilution, (thousands)	101,162	101,004	101,162	100,998	101,072	101,117	100,993

# Q2 2025

## Consolidated balance sheets

(Amounts in SEK 000s)	30 Jun 2025	30 Jun 2024	31 Dec 2024
<b>Assets</b>			
R&D projects in progress	842	46,240	767
Goodwill	153,552	174,246	175,104
Right-of-use assets	26,271	33,191	30,183
Property, plant, and equipment	166,453	180,955	175,436
Financial assets	28,013	28,013	28,013
Deferred tax assets	23,349	10,482	14,266
Deposits	45	51	52
<b>Total non-current assets</b>	<b>398,525</b>	<b>473,178</b>	<b>423,821</b>
Current assets excl. cash and cash equivalents	411,597	419,788	386,201
Cash and cash equivalents	622,343	1,007,742	1,223,984
<b>Total current assets</b>	<b>1,033,940</b>	<b>1,427,530</b>	<b>1,610,185</b>
<b>Total assets</b>	<b>1,432,464</b>	<b>1,900,708</b>	<b>2,034,006</b>
<b>Equity and liabilities</b>			
Equity attributable to owners of the Parent Company	1,154,712	1,575,310	1,723,932
Non-controlling interests	2	2	2
<b>Total equity</b>	<b>1,154,714</b>	<b>1,575,312</b>	<b>1,723,934</b>
Deferred tax liability	5,348	15,226	5,444
Non-current liabilities	92,162	90,164	98,425
Current liabilities	180,241	220,006	206,203
<b>Total liabilities and equity</b>	<b>1,432,464</b>	<b>1,900,708</b>	<b>2,034,006</b>

# Q2 2025

## Consolidated cash flow statements

(Amounts in SEK 000s)	Apr - Jun 2025	Apr - Jun 2024	Jan - Jun 2025	Jan - Jun 2024	Jan - Dec 2024
<b>Operating activities</b>					
Operating profit	108,346	135,377	205,483	278,560	423,371
Depreciation/amortization	6,197	6,148	12,395	11,890	76,695
Other non-cash items	-73	-1,657	2,143	-3,136	-3,537
Taxes	-27,881	-24,556	-59,451	-60,995	-111,515
Interest received and paid	4,389	8,364	11,275	20,026	37,918
<b>Cash flow from operating activities before changes in working capital</b>	<b>90,978</b>	<b>123,676</b>	<b>171,845</b>	<b>246,345</b>	<b>422,932</b>
Changes in working capital	-13,805	-4,551	-58,951	-75,293	-49,714
<b>Cash flow from operating activities</b>	<b>77,173</b>	<b>119,125</b>	<b>112,894</b>	<b>171,052</b>	<b>373,218</b>
<b>Investing activities</b>					
Purchase of property, plant, and equipment	-1,111	-2,233	-1,790	-11,006	-13,756
Purchase of intangible assets	-56	-8	-75	-9	-397
Sale of equipment	-	-	-	-	80
<b>Cash flow from investing activities</b>	<b>-1,167</b>	<b>-2,241</b>	<b>-1,865</b>	<b>-11,015</b>	<b>-14,073</b>
<b>Financing activities</b>					
Dividend	-698,020	-696,778	-698,020	-696,778	-696,778
Repayment of lease liability	-1,742	-2,345	-3,543	-4,627	-9,355
Provision to Foundation to Prevent Antibiotic Resistance	-	-	-	-	-4,400
New share issue	-	-	-	-	20,815
<b>Cash flow from financing activities</b>	<b>-699,762</b>	<b>-699,123</b>	<b>-701,563</b>	<b>-701,405</b>	<b>-689,718</b>
<b>Cash flow for the period</b>	<b>-623,756</b>	<b>-582,239</b>	<b>-590,534</b>	<b>-541,368</b>	<b>-330,573</b>
<b>Cash and cash equivalents at the beginning of the period</b>	<b>1,249,297</b>	<b>1,591,393</b>	<b>1,223,984</b>	<b>1,544,192</b>	<b>1,544,192</b>
Exchange difference in cash and cash equivalents	-3,197	-1,412	-11,107	4,918	10,365
<b>Cash and cash equivalents at the end of the period</b>	<b>622,343</b>	<b>1,007,742</b>	<b>622,343</b>	<b>1,007,742</b>	<b>1,223,984</b>

## Summary consolidated statement of changes in equity

(Amounts in SEK 000s)	Jan - Jun 2025	Jan - Jun 2024	Jan - Dec 2024
<b>Opening balance</b>	<b>1,723,934</b>	<b>2,030,344</b>	<b>2,030,344</b>
New share issue	-	-	20,815
Dividend	-698,020	-696,777	-696,778
Provision to Foundation to Prevent Antibiotic Resistance	-5,000	-4,400	-4,400
Share-based payments	372	-	-
Comprehensive income for the period	133,428	246,144	373,953
<b>Closing balance</b>	<b>1,154,714</b>	<b>1,575,312</b>	<b>1,723,934</b>

# Q2 2025

## Note 1. Reporting by segment – Group

Executive Management has analyzed the Group's internal reporting and determined that the Group's operations are monitored and evaluated based on the following segments:

- **Pediatrics segment** (drops, gut health tablets, oral rehydration solution (ORS), creams and cultures to be used as ingredients in licensee products (such as infant formula).

- **Adult Health segment** (gut health tablets, oral health lozenges and cultures as an ingredient in a licensee's dairy products, Nutraceuticals own products as well as royalty revenues for Adult Health products).

- **Other segment** (smaller segments such as royalty from packaging solutions).

For the above segments BioGaia reports net sales and gross profit, which are monitored regularly by the CEO (who is regarded as the chief operating decision maker) together with the Executive Management. There is no monitoring of the company's total assets and liabilities against the segments' assets and liabilities.

(Amounts in SEK 000s)	Apr - Jun 2025	Apr - Jun 2024	Jan - Jun 2025	Jan - Jun 2024	Jan - Dec 2024	Jul 2024 - Jun 2025	Jul 2023 - Jun 2024
<b>Revenue by segment</b>							
Pediatrics	310,080	304,809	579,974	597,088	1,093,278	1,076,164	1,072,930
Adult Health	89,762	78,200	184,353	153,019	321,288	352,621	288,684
Other	4,850	1,113	6,631	3,811	8,153	10,972	7,772
<b>Total</b>	<b>404,692</b>	<b>384,122</b>	<b>770,957</b>	<b>753,918</b>	<b>1,422,718</b>	<b>1,439,757</b>	<b>1,369,386</b>
<b>Gross profit by segment</b>							
Pediatrics	230,179	235,007	433,860	455,379	820,406	798,887	820,295
Adult Health	58,901	47,923	121,853	90,680	202,184	233,357	183,043
Other	4,800	1,111	6,532	3,811	8,153	10,873	7,772
<b>Total</b>	<b>293,881</b>	<b>284,041</b>	<b>562,245</b>	<b>549,870</b>	<b>1,030,743</b>	<b>1,043,118</b>	<b>1,011,110</b>
Selling, administrative, R&D expenses	-180,742	-142,858	-327,600	-277,880	-621,382	-671,102	-530,729
Other operating expenses/income	-4,792	-5,806	-29,161	6,570	14,010	-21,721	-1,753
Operating profit	108,346	135,377	205,483	278,560	423,371	350,294	478,628
Net financial items	2,055	7,375	6,830	17,791	24,448	13,487	33,936
<b>Profit before tax</b>	<b>110,401</b>	<b>142,752</b>	<b>212,313</b>	<b>296,351</b>	<b>447,819</b>	<b>363,781</b>	<b>512,564</b>
<b>Sales by geographical market</b>							
<b>APAC</b>							
Pediatrics	83,211	71,839	121,200	129,534	238,181	229,847	226,210
Adult Health	27,030	24,838	56,831	50,360	120,852	127,323	108,279
Other	1,457	818	2,736	3,360	6,798	6,175	6,592
<b>Total APAC</b>	<b>111,699</b>	<b>97,495</b>	<b>180,767</b>	<b>183,254</b>	<b>365,832</b>	<b>363,345</b>	<b>341,081</b>
<b>EMEA</b>							
Pediatrics	109,255	112,802	214,783	250,565	423,687	387,905	437,799
Adult Health	26,409	24,271	44,070	47,888	82,088	78,270	80,566
Other	990	283	1,489	441	1,336	2,384	1,136
<b>Total EMEA</b>	<b>136,655</b>	<b>137,357</b>	<b>260,342</b>	<b>298,893</b>	<b>507,110</b>	<b>468,559</b>	<b>519,501</b>
<b>Americas</b>							
Pediatrics	117,613	120,169	243,991	216,989	431,410	458,411	408,922
Adult Health	36,323	29,090	83,452	54,772	118,348	147,029	99,838
Other	2,402	10	2,405	10	18	2,413	44
<b>Total Americas</b>	<b>156,339</b>	<b>149,269</b>	<b>329,849</b>	<b>271,771</b>	<b>549,776</b>	<b>607,853</b>	<b>508,804</b>
<b>Total</b>	<b>404,692</b>	<b>384,122</b>	<b>770,957</b>	<b>753,918</b>	<b>1,422,718</b>	<b>1,439,757</b>	<b>1,369,386</b>

# Q2 2025

Date of recognition (Amounts in SEK 000s) Performance obligations met on specific date (Product sales)	Apr - Jun 2025	Apr - Jun 2024	Jan - Jun 2025	Jan - Jun 2024	Jan - Dec 2024
Pediatrics	310,080	304,809	573,304	597,088	1,093,278
Adult Health	86,407	75,164	179,026	147,680	311,003
Other	4,018	871	5,468	3,632	7,335
<b>Total</b>	<b>400,506</b>	<b>380,844</b>	<b>757,798</b>	<b>748,400</b>	<b>1,411,616</b>
<b>Performance obligations met over time (Royalty)</b>					
Pediatrics	-	-	6,670	-	-
Adult Health	3,354	3,036	5,327	5,339	10,285
Other	832	241	1,162	179	817
<b>Total</b>	<b>4,186</b>	<b>3,277</b>	<b>13,159</b>	<b>5,519</b>	<b>11,102</b>
<b>Total</b>	<b>404,692</b>	<b>384,121</b>	<b>770,957</b>	<b>753,918</b>	<b>1,422,718</b>

Note 2. Largest shareholders on 30 June 2025 (source: Vantage by Euroclear)

	Shares	Shares %	Votes	Votes %
1 Anatom Holding AG	7,357,533	7.27%	23,348,355	18.66%
2 Fjärde AP-fonden	8,200,182	8.11%	8,200,182	6.55%
3 Boleo Holding AG	1,012,590	1.00%	5,010,300	4.00%
4 Schember Holding AG	1,012,590	1.00%	5,010,300	4.00%
5 Premier Miton Investors	3,662,321	3.62%	3,662,321	2.93%
6 Cargill Inc	3,000,000	2.97%	3,000,000	2.40%
7 Handelsbanken Fonder AB	2,454,907	2.43%	2,454,907	1.96%
8 JP Morgan Asset Management	2,245,377	2.22%	2,245,377	1.79%
9 Allianz Global Investors	2,108,837	2.08%	2,108,837	1.69%
10 TIN Fonder	1,835,665	1.81%	1,835,665	1.47%
Other shareholders	68,272,308	67.49%	68,272,308	54.55%
<b>Total</b>	<b>101,162,310</b>	<b>100%</b>	<b>125,148,552</b>	<b>100%</b>

# Q2 2025

## Note 3. Fair value

### Financial liabilities

BioGaia has a financial liability relating to the additional purchase price in business acquisitions that is measured at fair value through profit or loss. The additional purchase price is due to the acquisition of Nutraceutics and is based on sales in Nutraceutics in 2026 or 2027. The amount, which will be settled in April 2027 or 2028, may also be adjusted if the agreed budget for marketing costs is exceeded.

Revaluation took place during the second quarter of 2025 and BioGaia's best assessment of fair value of the financial liability related to the additional purchase price on 30 June 2025 was therefore adjusted to SEK 59.6 million.

Estimates of fair value are based on Level 3 of the hierarchy for fair value, which means fair value is determined using valuation models where significant inputs are based on unobservable data. The measurement was based on anticipated future cash flows discounted with a market-based interest rate. The value adjustment is recognized as a financial expense of SEK 1.6 million (1.0) during the quarter. The weighted average cost of capital (WACC) amounted to 12.8% (12.7 % on 31 December 2024).

(Amounts in SEK 000s)	Jan - Jun	Jan - Jun	Jan - Dec
	2025	2024	2024
Opening balance	65,053	46,529	46,529
Value adjustment	3,486	2,240	13,483
Exchange difference	- 8,921	2,658	5,041
<b>Closing balance</b>	<b>59,618</b>	<b>51,427</b>	<b>65,053</b>

### Financial assets

BioGaia owns shares in the companies Boneprox AB and Skinome AB through BioGaia Invest. These financial assets are measured at fair value through profit or loss. Estimates of fair value are based on Level 3 of the hierarchy for fair value, which means fair value is determined using valuation models where significant inputs are based on unobservable data.

The fair values of other receivables, cash and cash equivalents, trade payables and other liabilities are estimated to be equal to their carrying amounts (amortized cost) due to the short maturities.

(Amounts in SEK 000s)	Jan - Jun	Jan - Jun	Jan - Dec
	2025	2024	2024
Opening balance	28,013	28,013	28,013
Value adjustment	-	-	-
Acquisitions	-	-	-
<b>Closing balance</b>	<b>28,013</b>	<b>28,013</b>	<b>28,013</b>

# Q2 2025

## Consolidated key ratios

(Amounts in SEK 000s)	Jan - Jun 2025	Jan - Jun 2024	Jan - Dec 2024
Net sales	770,957	753,918	1,422,718
Growth of net sales	2 %	11%	10%
Operating profit, SEK 000s	205,483	278,560	423,371
Adjusted operating profit, SEK 000s	205,483	280,819	477,622
Profit after tax, SEK 000s	168,103	232,857	351,388
Return on equity	12%	13%	19%
Return on capital employed	14%	16%	25%
Capital employed, SEK 000s	1,160,061	1,590,538	1,729,378
Number of shares, thousands	101,162	100,982	101,162
Average number of shares before dilution, thousands <sup>1)</sup>	101,162	100,982	101,072
Average number of shares after dilution, thousands <sup>1)</sup>	101,162	100,998	101,072
Earnings per share before dilution, SEK <sup>1)</sup>	1.66	2.31	3.48
Earnings per share after dilution, SEK <sup>1)</sup>	1.66	2.31	3.48
Equity per share, SEK	11.41	15.60	17.06
Equity/assets ratio	81%	83%	85%
Operating margin	27%	37%	30%
Adjusted operating margin	27%	37%	34%
Profit before tax margin	28%	39%	31%
Average number of employees	226	212	217

1) Key ratio defined according to IFRS.

A list of definitions of key ratios reported in the consolidated financial statements is provided on page 164 of BioGaia's annual report for 2024. In this report, BioGaia reports information used by Executive Management to assess the Group's development. Some of the key ratios presented are not defined according to IFRS. The company is of the opinion that these metrics provide valuable complementary information to stakeholders and the company's management since they contribute to evaluation of relevant trends and the company's performance. Since not all companies calculate

key ratios in the same manner, these are not always comparable to metrics used by other companies. These key ratios should therefore not be seen as a replacement for metrics defined according to IFRS. ESMA's guidelines on alternative performance measures are applied, which means extended disclosure requirements regarding key ratios not defined according to IFRS. A reconciliation of key ratios that BioGaia considers relevant according to these guidelines is provided below.

Key ratio	Definition/calculation	Purpose
<b>Adjusted operating margin</b>	Adjusted operating margin excluding items affecting comparability.	The adjusted measure provides enhanced understanding of the performance of operations.
<b>Adjusted operating profit</b>	Operating profit (earnings before financial items and tax) excluding items affecting comparability.	The adjusted measure provides enhanced understanding of the performance of operations.
<b>Average number of shares</b>	Time-weighted number of outstanding shares during the year taking bonus issue elements into account.	Used to calculate equity and earnings per share.
<b>Capital employed</b>	Total assets less interest-free liabilities.	Capital employed measures the company's ability, in addition to cash and liquid assets, to meet the requirements of business operations.
<b>Earnings per share</b>	Profit for the period attributable to owners of the Parent Company divided by the average number of shares (definition according to IFRS).	EPS measures how much of net profit is available for payment to the shareholders as dividends per share.
<b>Equity/assets ratio</b>	Shareholders' equity at the end of the period as a percentage of total assets.	A traditional metric to show financial risk expressed as the share of total assets financed by the shareholders. Shows the company's stability and ability to withstand losses.
<b>Equity per share</b>	Equity attributable to the owners of the Parent Company divided by the average number of shares.	Equity per share measures the company's net value per share and indicates whether a company will increase the shareholders' wealth over time.
<b>Gross margin</b>	Gross profit as a percentage of net sales.	The gross margin is used to measure profitability.
<b>Growth</b>	Sales for the period less sales for the year-earlier period divided by sales for the year-earlier period. Breakdown by foreign exchange, organic growth and acquisitions.	Shows the company's realized sales growth over time.
<b>Items affecting comparability</b>	Expenses in conjunction with restructuring, impairment and other items of a nature that affect comparability.	The separate recognition of items that affect comparability between different periods provides enhanced understanding of the company's financial performance.
<b>Operating margin (EBIT margin)</b>	Operating profit expressed as a percentage of net sales.	The operating margin is used to measure operational profitability.
<b>Profit before tax margin</b>	Profit before tax as a percentage of net sales.	This key ratio makes it possible to compare profitability regardless of the corporate income tax.
<b>Return on capital employed</b>	Profit before net financial items plus financial income as a percentage of average capital employed.	Return on capital employed is used to analyze profitability, based on the amount of capital used.
<b>Return on equity</b>	Profit attributable to the owners of the Parent Company divided by average equity attributable to the owners of the Parent Company.	Return on equity is used to measure profit generation, over time, given the resources attributable to the owners of the Parent Company.

# Q2 2025

## Key ratio

(Amounts in SEK 000s)	Jan - Jun 2025	Jan - Jun 2024	Jan - Dec 2024
<b>Return on equity</b>			
Profit attributable to owners of the Parent Company (A)	168,103	232,857	351,388
Equity attributable to owners of the Parent Company	1,154,712	1,575,310	1,723,932
Average equity attributable to owners of the Parent Company (B)	1,439,322	1,802,826	1,877,137
Return on equity (A/B)	12%	13%	19%
<b>Return on capital employed</b>			
Operating profit	205,483	278,560	423,371
Financial income	11,459	20,817	39,372
Profit before net financial items + financial income (A)	216,942	299,377	462,743
Total assets	1,432,464	1,900,708	2,034,006
Interest-free liabilities	-272,403	-310,170	-304,628
Capital employed	1,160,061	1,590,538	1,729,378
Average capital employed (B)	1,602,793	1,818,031	1,887,451
Return on capital employed (A/B)	14%	16%	25%

## Key ratio

(Amounts in SEK 000s)	30 Jun 2025	30 Jun 2024	31 Dec 2024
<b>Equity/assets ratio</b>			
Equity (A)	1,154,714	1,575,312	1,723,934
Total assets (B)	1,432,464	1,900,708	2,034,006
Equity/assets ratio (A/B)	81%	83%	85%
<b>Operating margin</b>			
Operating profit (A)	205,483	278,560	423,371
Net sales (B)	770,957	753,918	1,422,718
Operating margin (A/B)	27%	37%	30%
<b>Profit before tax margin</b>			
Profit before tax (A)	212,313	296,351	447,819
Net sales (B)	770,957	753,918	1,422,718
Profit before tax margin (A/B)	28%	39%	31%
<b>Equity per share</b>			
Equity attributable to owners of the Parent Company (A)	1,154,712	1,575,310	1,723,932
Average number of shares (B)	101,162	100,982	101,072
Equity per share (A/B)	11.41	15.60	17.06

# Q2 2025

## Change in sales by segment (including and excluding foreign exchange effects)

		Pediatrics		Adult Health		Other		Total	
(Amounts in SEK 000s)		Apr - Jun 2025	Jan - Jun 2025	Apr - Jun 2025	Jan - Jun 2025	Apr - Jun 2025	Jan - Jun 2025	Apr - Jun 2025	Jan - Jun 2025
Description									
A	Previous year's net sales according to the average rate	304,809	597,087	78,200	153,019	1,113	3,813	384,122	753,918
B	Net sales for the year according to the average rate	310,080	579,974	89,762	184,353	4,850	6,630	404,692	770,957
C	Recognized change (B-A)	5,271	-17,113	11,562	31,334	3,737	2,817	20,570	17,038
	Percentage change (C/A)	2%	-3%	15%	20%	336%	74%	5%	2%
D	Net sales for the year according to the previous year's average rate	333,466	596,149	96,427	188,508	4,850	6,630	434,743	791,287
E	Foreign exchange effects (B-D)	-23,386	-16,175	-6,665	-4,155	0	0	-30,051	-20,330
	Percentage change (E/A)	-8%	-3%	-9%	-3%	0%	0%	-8%	-3%
F	Organic change (C-E)	28,657	-938	18,227	35,489	3,737	2,817	50,621	37,368
	Organic change, % (F/A)	9%	0%	23%	23%	336%	74%	13%	5%

Average key exchange rates	Apr - Jun 2025	Apr - Jun 2024	Jan - Jun 2025	Jan - Jun 2024	Jan - Dec 2024
EUR	10.91	11.61	11.12	11.38	11.41
USD	9.71	10.67	10.21	10.49	10.52
JPY	0.0670	0.0683	0.0683	0.0691	0.0699

Closing date key exchange rates	30 Jun 2025	30 Jun 2024	31 Dec 2024
EUR	11.15	11.36	11.49
USD	9.51	10.61	11.00
JPY	0.0659	0.0661	0.0698

Pledged assets and contingent liabilities - Group (Amounts in SEK 000s)	30 Jun 2025	30 Jun 2024	31 Dec 2024
Pledged assets	None	None	None
Contingent liabilities	None	None	None

Adjusted operating profit - Group (Amounts in SEK 000s)	Apr - Jun 2025	Apr - Jun 2024	Jan - Jun 2025	Jan - Jun 2024	Jan - Dec 2024
Operating profit	108,346	135,377	205,483	278,560	423,371
Items affecting comparability	-	-2,741	-	2,259	54,251
Adjusted operating profit	108,346	132,636	205,483	280,819	477,622

# Q2 2025

## Summary statements of comprehensive income – Parent Company

### Parent Company income statement

(Amounts in SEK 000s)	Jan - Jun 2025	Jan - Jun 2024	Jan - Dec 2024
Net sales	586,078	623,938	1,121,581
Cost of sales	-205,276	-228,500	-407,727
Gross profit	380,802	395,438	713,854
Selling expenses	-94,897	-88,215	-191,197
Administrative expenses	-23,086	-18,618	-39,057
Research and development expenses	-47,082	-49,780	-147,888
Other operating income/expenses	-29,252	6,647	14,038
Operating profit	186,485	245,472	349,750
Impairment loss on shares in subsidiaries	-21,142	-	-2,704
Net financial items	9,842	18,055	66,223
Profit before tax	175,185	263,527	413,269
Tax	-39,465	-54,147	-78,849
<b>Profit for the period</b>	<b>135,720</b>	<b>209,380</b>	<b>334,420</b>

### Parent Company balance sheet

(Amounts in SEK 000s)	30 Jun 2025	30 Jun 2024	31 Dec 2024
<b>Assets</b>			
R&D projects in progress	842	46,240	767
Property, plant, and equipment	7,625	9,596	8,315
Shares in Group companies	244,912	252,575	256,307
Non-current receivables from subsidiaries	7,785	-	5,516
Deferred tax assets	3,987	1,537	2,442
<b>Total non-current assets</b>	<b>265,152</b>	<b>309,948</b>	<b>273,347</b>
Current assets excl. cash and cash equivalents	352,449	338,274	291,220
Cash and cash equivalents	391,834	769,291	976,509
<b>Total current assets</b>	<b>744,283</b>	<b>1,107,565</b>	<b>1,267,729</b>
<b>Total assets</b>	<b>1,009,435</b>	<b>1,417,513</b>	<b>1,541,076</b>
<b>Equity and liabilities</b>			
<b>Total equity</b>	<b>759,014</b>	<b>1,180,151</b>	<b>1,326,007</b>
Deferred tax liability	-	9,445	-
Non-current liabilities	6,440	-	-
Interest-free current liabilities	243,981	227,917	215,069
<b>Total liabilities and equity</b>	<b>1,009,435</b>	<b>1,417,513</b>	<b>1,541,076</b>

# Q2 2025

## Parent Company cash flow statement

(Amounts in SEK 000s)	Jan - Jun 2025	Jan - Jun 2024	Jan - Dec 2024
<b>Operating activities</b>			
Operating profit	186,485	245,472	349,750
Depreciation/amortization	876	1,136	48,213
Other non-cash items	6,780	-2,887	-4,496
Taxes	-42,947	-48,550	-87,597
Interest received and paid	9,842	18,055	36,223
<b>Cash flow from operating activities before changes in working capital</b>	<b>161,035</b>	<b>213,226</b>	<b>342,093</b>
Changes in working capital	-29,036	-35,439	4,454
<b>Cash flow from operating activities</b>	<b>132,000</b>	<b>177,787</b>	<b>346,547</b>
<b>Investing activities</b>			
Purchase of intangible assets	-75	-9	-397
Purchase of property, plant, and equipment	-186	-633	-633
Purchase of financial assets	-9,748	-5,000	-14,242
Sale of equipment	-	-	80
Dividend received	-	-	30,000
<b>Cash flow from investing activities</b>	<b>-10,009</b>	<b>-5,642</b>	<b>14,808</b>
<b>Financing activities</b>			
Dividend	-698,020	-696,778	-696,778
Provision to Foundation to Prevent Antibiotic Resistance	-	-	-4,400
New share issue	-	-	20,815
<b>Cash flow from financing activities</b>	<b>-698,020</b>	<b>-696,778</b>	<b>-680,363</b>
<b>Cash flow for the period</b>	<b>-576,030</b>	<b>-524,633</b>	<b>-319,008</b>
<b>Cash and cash equivalents at the beginning of the period</b>	<b>976,509</b>	<b>1,291,037</b>	<b>1,291,037</b>
Exchange difference in cash and cash equivalents	-8,645	2,887	4,480
<b>Cash and cash equivalents at the end of the period</b>	<b>391,834</b>	<b>769,291</b>	<b>976,509</b>

## Summary Parent Company statement of changes in equity

(Amounts in SEK 000s)	Jan - Jun 2025	Jan - Jun 2024	Jan - Dec 2024
<b>Opening balance</b>	<b>1,326,007</b>	<b>1,671,949</b>	<b>1,671,949</b>
Dividend	-698,020	-696,778	-696,778
Provision to Foundation to Prevent Antibiotic Resistance	-5,000	-4,400	-4,400
Share-based payments	308	-	-
New issue warrants	-	-	20,816
Comprehensive income for the period	135,720	209,380	334,420
<b>Closing balance</b>	<b>759,014</b>	<b>1,180,151</b>	<b>1,326,007</b>

# Q2 2025

## Financial calendar



🕒 8:00 a.m. CET Interim management statement  
1 January – 30 September 2025

The Board of Directors and the President and CEO declare that the six-month Interim Report provides a true and fair overview of the Parent Company’s and Group’s operations, their financial position and performance, and describes material risks and uncertainties facing the Parent Company and other companies in the Group.

**Stockholm, 18 July 2025**

<b>Peter Rothschild</b> Board Chairman	<b>David Dangoor</b> Board Vice Chairman	<b>Outi Armstrong</b> Member of the Board
<b>Bénédicte Flambard</b> Member of the Board	<b>Barbro Fridén</b> Member of the Board	<b>Anthon Jahreskog</b> Member of the Board
<b>Vanessa Rothschild</b> Member of the Board		
<b>Theresa Agnew</b> President and CEO		

# Q2 2025

## Auditor's review report

### Introduction

We have reviewed the interim report of BioGaia AB (publ), for the period 1 January – 30 June 2025. The Board of Directors and the CEO are responsible for the preparation and presentation of this interim report in accordance with IAS 34 and the Annual Accounts Act. Our responsibility is to express a conclusion on this interim report based on our review.

### Scope of review

We conducted our review in accordance with the International Standard on Review Engagements ISRE 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity. A review consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review has a different focus and is substantially less in scope than an audit conducted in accordance with International Standards on Auditing (ISA) and other generally accepted auditing practices. The procedures performed in a review do not enable us to obtain a level of assurance that would make us aware of all significant matters that might be identified in an audit. Therefore, the conclusion expressed based on a review does not give the same level of assurance as a conclusion expressed based on an audit.

### Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the interim report is not, in all material respects, prepared for the Group in accordance with IAS 34 and the Annual Accounts Act, and for the Parent Company in accordance with the Annual Accounts Act.

Stockholm, 18 July 2025

Deloitte AB

Jenny Holmgren

Authorised Public Accountant

## BioGaia AB



### The company

BioGaia is a Swedish world-leading probiotic company that has been at the forefront of microbiome research for more than 35 years. Our vision is to be the most trusted probiotic brand in the world. We develop, manufacture, market, and sell probiotic products for gut, oral, and immune health. The products are primarily based on different strains of the lactic acid bacterium *Limosilactobacillus reuteri*, *L. reuteri* (formerly *Lactobacillus*).

The class B shares of the Parent Company BioGaia AB are quoted on the Mid Cap List of Nasdaq Stockholm.

### Business model

BioGaia has two types of distribution – sales through distribution partners and direct sales (subsidiaries). Most of BioGaia's revenue comes from the sale of gut health products, such as colic drops, immune- and oral health products. Revenues also include the sale of bacterial cultures to be used in licensee products, such as infant formula and dairy products, as well as royalties for the use of *L. reuteri* in licensee products. BioGaia's products are available in more than 100 countries through partnerships with nutrition and pharmaceutical companies, as well as through our own subsidiaries.

BioGaia's direct distribution, through subsidiaries, extends across nine countries (Sweden, Finland, France, the UK, USA, Canada, Australia, New Zealand and Japan).

BioGaia holds patents for the use of certain strains of *L. reuteri* and certain packaging solutions in all major markets. At the end of 2024, BioGaia held more than 600 granted patents for various bacteria strains and territories.

### The BioGaia brand

BioGaia launched its own consumer brand in 2006. Today, several BioGaia's distribution partners sell finished products under the BioGaia brand in several markets. One important element of BioGaia's brand strategy is to increase the percentage of sales under the BioGaia brand. Of products (drops, tablets for gut and oral health, oral rehydration, etc.) sold in 2024, 92% (90%) were sold under the BioGaia brand including co-branding.

Some of BioGaia's distributors sell finished consumer products under their own brand names. On these products, the BioGaia brand is shown on the consumer package since BioGaia is both the manufacturer and licensor.

BioGaia's licensees add *L. reuteri* culture to their products and sell these under their own brand names. On these products, the BioGaia brand is most often shown on the package as the licensor/patent holder.

### Research and clinical studies

BioGaia's strains of *L. reuteri* are among the most studied in the world, in particular studies in young children, with strong pre-clinical and clinical evidence. As of December 2024, over 270 clinical studies with BioGaia's various strains of *L. reuteri* have been performed. These studies involved more than 23,000 individuals of all ages.

### Over the years, BioGaia has performed studies in the following areas:

- Colic and constipation in infants
- Immune modulation and infection prevention
- Acute diarrhea
- Antibiotic-associated side effects, such as diarrhea
- Treatment of *H. pylori* infections
- Irritable bowel syndrome (IBS)
- Oral health, such as gingivitis (inflammation of the gums) and periodontitis (loosening of the teeth)
- Osteopenia
- Autism spectrum condition
- Urinary tract infections

**BioGaia AB** Box 3242 SE-103 64 STOCKHOLM

Street address: Kungsbrogatan 3, Stockholm

Telephone: +46 8 555 293 00, Corporate identity no. 556380-8723, [www.biogaiaigroup.com](http://www.biogaiaigroup.com)